- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940842
AI Voice Calls Versus Text and Email Reminders for Questionnaire Response After Shoulder Arthroplasty (VOICE-REACH)
Proactive Conversational Artificial Intelligence Calls Versus Digital Reminders to Collect Patient-Reported Outcomes After Shoulder Arthroplasty: A Randomized Study Within a Multicenter Cohort
After shoulder replacement surgery, surgeons send questionnaires to their patients to learn how they are doing (pain, shoulder function, satisfaction). Many patients do not answer. This study tests the best way to obtain these answers.
The study is nested in a multicenter study of pain after shoulder arthroplasty conducted in four French centers (host study RetroPAinRSACAll, supported by Ramsay Santé). The clinical results of the host study are not the subject of this registration: this study evaluates only the method used to collect the information.
All patients first receive an email invitation (when an email address is available) and, the next day, a text message (SMS) with a personal link to the questionnaire and a phone number to answer at any time by talking with an automated voice assistant. Patients who have not answered two days after the first contact are randomly assigned to one of two follow-up strategies: (1) further digital reminders (SMS on day 3 and day 5, email on day 7), or (2) up to three phone calls from a conversational artificial intelligence (AI) voice agent on days 3, 5 and 7, which asks the same questions orally. In both groups, patients can answer at any time online or by calling the voice assistant, and contacts stop as soon as the questionnaire is completed or the patient refuses.
The main outcome is the proportion of patients who complete the questionnaire within 14 days of the first contact.
Study Overview
Status
Intervention / Treatment
Detailed Description
Design. VOICE-REACH is a pragmatic, multicenter, individually randomized, two-arm, open-label superiority study within a trial (SWAT). It is embedded in the host study RetroPAinRSACAll (persistent pain after shoulder arthroplasty, four French shoulder surgery centers, favorable opinion of the Ramsay Santé scientific committee, reference COS-RGDS-2026-07-008). All patients of the host cohort are contacted through the DeepCall platform on behalf of their surgeon to complete the host study questionnaire (operation details, warning signs, pain screening and characterization, rehabilitation and function including the Subjective Shoulder Value, opinion on the operation and on the contact). The comparison concerns the follow-up strategy only: the questionnaire is the same in both arms and the same on the web and by voice.
Common phase (all participants). Day 0: email invitation with a personal questionnaire link, sent when an email address is available. Day 1: SMS with the same link, the phone number of the AI voice agent (available 24 hours a day for inbound calls) and an opt-out option (reply NO). Patients are contacted in successive waves of up to 450 patients, one day apart, to respect operator sending limits; all study days are counted from each participant's own day 0.
Randomization. On day 2, participants who have not completed the questionnaire and have not refused are randomized 1:1 by the platform, using a computer-generated permuted block sequence (blocks of 4) stratified by center. Participants who completed the questionnaire before day 2 are not randomized and are described separately.
Arm A, digital reminders: SMS reminders on day 3 and day 5 and an email reminder on day 7 (when an email address is available).
Arm B, proactive AI calls: outbound calls from the AI voice agent on day 3, day 5 and day 7 (up to three attempts). The agent calls on behalf of the surgeon's team and asks the questionnaire orally; answers are extracted into the same structured fields as the web form.
In both arms, the web link and the inbound voice line remain available throughout, and all scheduled contacts stop as soon as the questionnaire is completed, the patient refuses, or the patient is identified as deceased. Warning signs reported by patients are flagged to the surgical team for review; the AI agent does not give medical advice.
Analysis. The primary analysis is intention to treat among all randomized participants: proportion with a completed questionnaire by day 14, risk difference (Arm B minus Arm A) with 95% confidence interval, adjusted for center and email availability. Participants without a completed questionnaire by day 14 are counted as non-completers; no answer is imputed. Secondary analyses describe the yield of the common phase, time to completion, completion channel, partial responses, refusals, number of contacts and cost per completed questionnaire, acceptability of the contact mode among responders, representativeness of responders, and the accuracy of voice-captured answers.
Registration timing. The common pre-randomization outreach started on 9 November 2026. This record was created on 10 November 2026, before the first randomization (day 2 of the first wave, 11 November 2026).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jules Descamps, MD
- Phone Number: 0698270789
- Email: dr.jdescamps@gmail.com
Study Locations
-
-
-
Caen, France, 14000
- Recruiting
- Hôpital Privé Saint-Martin
-
Principal Investigator:
- Franck Dordain, MD
-
Lyon, France, 69008
- Recruiting
- Centre Orthopédique Santy, Hôpital Privé Jean Mermoz
-
Principal Investigator:
- Arnaud Godenèche, MD
-
Paris, France, 75019
- Recruiting
- Clinique des Maussins-Nollet
-
Principal Investigator:
- Geoffroy Nourissat, MD, PhD
-
Strasbourg, France, 67000
- Recruiting
- Clinique de l'Orangerie
-
Principal Investigator:
- Maxime Antoni, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- Shoulder arthroplasty (reverse, anatomic, humeral head replacement or revision arthroplasty) performed at one of the four participating centers and listed in the host study cohort
- At least one telephone number available (an email address is not required)
Additional criteria for randomization (day 2):
* Questionnaire not completed and no refusal at the day-2 cutoff
Exclusion Criteria:
- Death identified before the first contact (cross-check with the French national death registry, INSEE)
- Duplicate record
- Refusal of contact
- Questionnaire already completed before day 2 (excluded from randomization only, described separately)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Digital Reminders
Common phase: email invitation on day 0 (if an email address is available) and SMS invitation on day 1 with the questionnaire link and the AI voice agent phone number. After randomization on day 2: SMS reminder on day 3, SMS reminder on day 5 and email reminder on day 7 (if an email address is available). Participants can answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal. |
Standardized reminder messages sent by the DeepCall platform on behalf of the surgeon: SMS on day 3 and day 5 and email on day 7 (if an email address is available), each with the personal questionnaire link, the AI voice agent phone number and an opt-out option. |
|
Experimental: Proactive AI Voice Calls
Same common phase (email on day 0 if available, SMS on day 1). After randomization on day 2: up to three outbound calls from the conversational AI voice agent on day 3, day 5 and day 7, during which the same questionnaire is asked orally. Participants can also answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal. |
Outbound telephone calls placed by a conversational AI voice agent (DeepCall platform) on day 3, day 5 and day 7, up to three attempts. The agent calls on behalf of the surgeon's team, conducts the same questionnaire orally and records the answers in the same structured fields as the web form.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire Completion by Day 14 Among Randomized Participants
Time Frame: From day 0 (first contact) to day 14
|
Proportion of randomized participants with a completed questionnaire within 14 days of their first contact (day 0), whatever the channel used (web link, inbound call or outbound AI call). A questionnaire is complete when it was submitted on the web or when all required items were answered during a voice interview. Participants without a completed questionnaire at the day-14 cutoff are counted as non-completers. Compared between arms (proactive AI voice calls minus digital reminders). |
From day 0 (first contact) to day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire Completion by Day 7 Among Randomized Participants
Time Frame: From day 0 to day 7
|
Proportion of randomized participants with a completed questionnaire by day 7, whatever the channel used. |
From day 0 to day 7
|
|
Time to Questionnaire Completion
Time Frame: From day 2 to day 14
|
Time in hours from randomization (day 2) to questionnaire completion among randomized participants; participants without a completed questionnaire are censored at day 14. |
From day 2 to day 14
|
|
Questionnaire Completion Before Randomization
Time Frame: From day 0 to day 2
|
Proportion of all enrolled participants who completed the questionnaire after the common email (day 0) and SMS (day 1) invitations, before the day-2 randomization. |
From day 0 to day 2
|
|
Questionnaire Completion by Day 14 in All Enrolled Participants
Time Frame: From day 0 to day 14
|
Proportion of all enrolled participants, randomized or not, with a completed questionnaire by day 14. |
From day 0 to day 14
|
|
Partial Questionnaire Response
Time Frame: From day 0 to day 14
|
Proportion of randomized participants who answered at least one question without completing the questionnaire by day 14. |
From day 0 to day 14
|
|
Completion Channel
Time Frame: From day 0 to day 14
|
Distribution of completed questionnaires by channel (web link, inbound call to the voice agent, outbound AI call), by arm. |
From day 0 to day 14
|
|
Refusal of Contact
Time Frame: From day 2 to day 14
|
Proportion of randomized participants who explicitly refused further contact (SMS reply, email refusal link or refusal during a call). |
From day 2 to day 14
|
|
Number of Contacts per Completed Questionnaire
Time Frame: From day 0 to day 14
|
Number of emails, SMS and outbound calls sent or attempted, divided by the number of completed questionnaires, by arm. |
From day 0 to day 14
|
|
Direct Cost per Completed Questionnaire
Time Frame: From day 0 to day 14
|
Direct costs of messaging, telephony and AI processing (euros) divided by the number of completed questionnaires, by arm, and incremental cost per additional completed questionnaire. |
From day 0 to day 14
|
|
Satisfaction With the Mode of Contact
Time Frame: From day 0 to day 14
|
Among participants who completed the questionnaire: satisfaction with the way they were contacted, rated on a 5-level scale from very satisfied to very dissatisfied. |
From day 0 to day 14
|
|
Perceived Number of Contacts
Time Frame: From day 0 to day 14
|
Among participants who completed the questionnaire: perceived number of contacts (too many, appropriate, too few). |
From day 0 to day 14
|
|
Preferred Contact Mode for Future Follow-up
Time Frame: From day 0 to day 14
|
Among participants who completed the questionnaire: preferred mode of contact for future follow-up questionnaires (categorical). |
From day 0 to day 14
|
|
Characteristics of Responders Versus Non-Responders
Time Frame: Day 14
|
Age, center, type of arthroplasty and time since surgery (when available in the host cohort) compared between participants who completed the questionnaire and those who did not, by arm (standardized differences). |
Day 14
|
|
Agreement Between Voice-Captured Answers and Human Review
Time Frame: From day 0 to day 14
|
In a random sample of completed voice interviews, agreement between the answers extracted by the AI agent and those coded by a reviewer listening to the recording, blinded to the extracted values (percentage agreement, kappa or intraclass correlation coefficient). |
From day 0 to day 14
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delivery of Email and SMS Invitations
Time Frame: From day 0 to day 7
|
Proportion of emails and SMS delivered, bounced or filtered by the operator, as reported by the sending providers. |
From day 0 to day 7
|
|
Outbound Call Outcomes
Time Frame: From day 3 to day 7
|
Distribution of outbound AI call outcomes (answered, voicemail, no answer, filtered, failed) and call duration in the proactive AI voice calls arm. |
From day 3 to day 7
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jules Descamps, MD, MSc, Hopital Lariboisière
- Study Chair: Geoffroy Nourissat, MD, PhD, Clinique des Maussins-Nollet, Ramsay Santé
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VOICE-REACH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Identifiable data, call recordings and transcripts will not be shared. Aggregated results will be published.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.